TRex Bio (NASDAQ:TRXB) Major Shareholder Purchases 178,571 Shares of Stock

TRex Bio, Inc. (NASDAQ:TRXB) major shareholder Alexandria Venture Investments bought 178,571 shares of TRex Bio stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the acquisition, the insider directly owned 1,346,501 shares in the company, valued at approximately $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

TRex Bio Price Performance

Shares of TRex Bio stock traded up $0.66 during trading on Thursday, hitting $14.16. The company’s stock had a trading volume of 88,697 shares, compared to its average volume of 200,681. TRex Bio, Inc. has a 52 week low of $13.21 and a 52 week high of $15.50.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.